Bortezomib restrains M2 polarization and reduces CXCL16-associated CXCR6+CD4 T cell chemotaxis in bleomycin-induced pulmonary fibrosis
CD4-Positive T-Lymphocytes
Male
Antigens, Differentiation, T-Lymphocyte
Macrophage
Pulmonary Fibrosis
RM1-950
QD415-436
Biochemistry
Pulmonary fibrosis
Bortezomib
Bleomycin
Mice
03 medical and health sciences
Antigens, CD
Animals
Lectins, C-Type
Receptors, CXCR6
0303 health sciences
Macrophages
Chemotaxis
Chemokine CXCL16
CXCR6
CXCL16
Mice, Inbred C57BL
Disease Models, Animal
Therapeutics. Pharmacology
Research Article
DOI:
10.1186/s10020-024-00836-5
Publication Date:
2024-05-24T15:02:08Z
AUTHORS (10)
ABSTRACT
Abstract Background The development of pulmonary fibrosis involves a cascade events, in which inflammation mediated by immune cells plays pivotal role. Chemotherapeutic drugs have been shown to dual effects on fibrosis, with bleomycin exacerbating and bortezomib alleviating tissue fibrotic processes. Understanding the intricate interplay between chemotherapeutic drugs, responses, is likely serve as foundation for crafting tailored therapeutic strategies. Methods A model bleomycin-induced was established, followed treatment bortezomib. Tissue samples were collected analysis cell subsets functional assessment flow cytometry vitro experiments. Additionally, multi-omics conducted further elucidate expression chemokines chemokine receptors, well characteristics populations. Results Here, we observed that CXCL16 CXCR6 elevated lung model. In context or TGF-β1 stimulation vitro, macrophages exhibited an M2-polarized phenotype secreted more than those control group. Moreover, revealed increased levels CD69 CD4 T during progression. administration alleviated accompanied reduced ratio decreased accumulation expressing CXCR6. Conclusions Our findings provide insights into key players involved offer preclinical evidence supporting repurposing strategy combination approaches reduce fibrosis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (40)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....